Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831552 · ClinicalTrials.gov registry record · NA
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
A NA study of Neuroblastoma and High-risk Neuroblastoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 84
- Enrollment target
- 6
- Study locations
NCT06831552 is a NA study of Neuroblastoma and High-risk Neuroblastoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 84 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (65% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT06831552, a NA study of Neuroblastoma and High-risk Neuroblastoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes. Participants will be randomized to receive one of the following for 6-months: * Usual supportive care alone or * Usual supportive care plus Pediatric RISE
Conditions Studied
Interventions
- BEHAVIORAL RISE Intervention
Study Locations (6)
Connecticut
- Connecticut Children's Medical Center - Hartford
Georgia
- Children's Healthcare of Atlanta - Atlanta
Massachusetts
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2029-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06831552
The ClinicalTrials.gov registry entry for NCT06831552 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (65% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which RISE Intervention is the first listed.
NCT06831552 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Connecticut, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06831552 about?
NCT06831552 is a clinical study titled "Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma". The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centere...
What is the current status of trial NCT06831552?
This trial is currently recruiting. It is a NA study. The enrollment target is 84 participants. The study started on 2025-04-30. Estimated completion is 2029-06-01.
What conditions does trial NCT06831552 study?
This clinical trial studies the following conditions: Neuroblastoma, High-risk Neuroblastoma.
What interventions are being tested in trial NCT06831552?
The interventions under investigation include: RISE Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06831552?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831552 being conducted?
This trial has 6 study locations across Connecticut, Georgia, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Phase II Study of Proton Radiation Therapy for Neuroblastoma
RECRUITING · NA
-
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
ACTIVE NOT RECRUITING · NA
-
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
COMPLETED · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.